Lazard Asset Management LLC Purchases New Position in Codexis, Inc. (NASDAQ:CDXS)

Lazard Asset Management LLC purchased a new stake in Codexis, Inc. (NASDAQ:CDXSGet Rating) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 6,357 shares of the biotechnology company’s stock, valued at approximately $66,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Codexis in the first quarter valued at approximately $33,000. SG Americas Securities LLC acquired a new stake in shares of Codexis in the second quarter valued at approximately $109,000. Strs Ohio boosted its holdings in shares of Codexis by 65.2% in the second quarter. Strs Ohio now owns 10,900 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 4,300 shares during the period. Walleye Capital LLC acquired a new stake in shares of Codexis in the second quarter valued at approximately $123,000. Finally, US Bancorp DE boosted its holdings in shares of Codexis by 43.7% in the second quarter. US Bancorp DE now owns 12,046 shares of the biotechnology company’s stock valued at $126,000 after acquiring an additional 3,666 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director John J. Nicols sold 35,716 shares of the firm’s stock in a transaction on Friday, October 28th. The stock was sold at an average price of $5.53, for a total value of $197,509.48. Following the completion of the transaction, the director now owns 943,106 shares in the company, valued at $5,215,376.18. The sale was disclosed in a document filed with the SEC, which is available at this link. 7.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on CDXS. StockNews.com raised Codexis from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright decreased their price objective on Codexis from $25.00 to $15.00 and set a “buy” rating for the company in a report on Monday, November 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Codexis has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Codexis Stock Performance

NASDAQ:CDXS opened at $5.44 on Friday. The stock has a fifty day moving average price of $5.82 and a two-hundred day moving average price of $7.97. The stock has a market capitalization of $357.35 million, a price-to-earnings ratio of -11.33 and a beta of 1.49. Codexis, Inc. has a 1 year low of $4.81 and a 1 year high of $39.21.

Codexis Profile

(Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Further Reading

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXSGet Rating).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.